Alclometasone Dipropionate
FDA-approved product (ointment, topical), marketed as Aclovate, Alclometasone Dipropionate.
- Registered studies
- 2
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Eye inflammation
- Skin disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Corticosteroids, moderately potent (group ii); Corticosteroids, plain
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA50.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli47.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae36.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis47.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
2registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Alclometasone Dipropionate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- TicagrelorExisting use: Acute coronary syndrome, Acute myocardial infarction, Coronary artery disease and 6 more62.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Quinapril HydrochlorideExisting use: Cardiovascular disease, Diabetes mellitus, Heart failure and 3 more62.3% AI-predicted activityagainst M. tuberculosis33 registered studies
- BelzutifanExisting use: Clear cell renal carcinoma, Hemangioblastoma, Neoplasm and 4 more62.2% AI-predicted activityagainst M. tuberculosis45 registered studies
- ChlorprothixeneExisting use: Psychosis62.2% AI-predicted activityagainst M. tuberculosis4 registered studies
- CrizotinibExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma62.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Pacritinib CitrateExisting use: Neoplasm, Polycythemia vera, Primary myelofibrosis62.2% AI-predicted activityagainst M. tuberculosis2 registered studies
- PralatrexateExisting use: Cancer, Mature T-cell and NK-cell non-Hodgkin lymphoma, Neoplasm and 2 more62.1% AI-predicted activityagainst M. tuberculosis44 registered studies
- Methdilazine HydrochlorideExisting use: Allergic disease62.0% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SirolimusExisting use: Adenoma sebaceum, Angiofibroma, Cancer and 5 more62.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AdagrasibExisting use: Neoplasm, Non-small cell lung carcinoma61.9% AI-predicted activityagainst M. tuberculosis40 registered studies
- TrandolaprilExisting use: Cardiovascular disease, Heart failure, Hypertension and 2 more61.9% AI-predicted activityagainst M. tuberculosis29 registered studies
- Almotriptan MalateExisting use: Migraine disorder61.8% AI-predicted activityagainst M. tuberculosis16 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO
NCT01465802 · start 2011-12-26
Registered record
- Registry ID
- NCT01465802
- Conditions
- Non Small Cell Lung Cancer (NSCLC)
- Interventions
- Dacomitinib; Dacomitinib; Doxycycline; Probiotic; Alclometasone cream
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2011-12-26
- Completion
- 2015-05-18
- Enrolment
- 236
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNon Small Cell Lung Cancer (NSCLC)InterventionDacomitinib; Dacomitinib; Doxycycline; Probiotic +1 morePhasePhase 2Registry statusCompletedStudy to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream
NCT02075632 · start 2006-09
Registered record
- Registry ID
- NCT02075632
- Conditions
- Eczema; Allergy Symptoms; Psoriasis; Itch
- Interventions
- Alclometasone dipropionate cream
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2006-09
- Completion
- 2006-11
- Enrolment
- 310
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEczema; Allergy Symptoms; Psoriasis; ItchInterventionAlclometasone dipropionate creamPhasePhase 2Registry statusCompleted